During a live event, Megan Kruse, MD, discussed NCCN guidelines and key therapies for patients with HR-positive metastatic ...

Urodynamics investigation to identify detrusor overactivity before proceeding to invasive overactive bladder treatments do not appear helpful.

VERV’s VERVE-102 showed an impressive 69% LDL-C reduction in its early Phase 1b data. Click here to find out why I rate VERV ...

Huntington Beach defense firm Karman Holdings acquires refractory metal products specialist Metal Technology Inc. (MTI) for ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Researchers sought to determine whether mosunetuzumab would have long-term efficacy in patients with follicular lymphoma.

The following is a summary of “CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic ...